All In Biotech

Drug Trial Radar · NCT05139602

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy: Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects Naïve to Biologic Therapy

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Actual

Start

Dec 28, 2021

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS. In the Main Study, participants will be put in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that participants will be assigned to placebo. Around 160 adult participants with moderate to severe HS who have failed anti-TNF therapy will be enrolled in the study at approximately 50 sites worldwide. In the Sub-study, participants will be put in 1 of 2 groups, called treatment arms. Both arms will receive treatment at different dosing intervals. Around 40 adult participants with moderate to severe HS who are naïve to biologic therapy will be enrolled in the study at approximately 20 sites. In the Main Study, participants will receive subcutaneous injections of lutikizumab (ABT-981) or placebo every week for 16 weeks. In the Sub-study, participants will receive subcutaneous injections of lutikizumab (ABT-981) every week for the first 15 weeks, then either every week or every other week for 36 weeks. There will be an optional Long Term Extension (LTE) for participants who completed Week 52 of the Sub-study and, as confirmed by the investigator, have shown a therapeutic benefit to study drug. Participants would then received lutikizumab using the same assigned dosing regimen as that from Period 2 of the Sub-study for an additional 104 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • LutikizumabBiological

    Subcutaneous Injection

  • PlaceboDrug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR)Time frame: Week 16
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 68

Locations

54 sites in 8 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists /ID# 240641

    Phoenix, Arizona

  • Mayo Clinic - Scottsdale /ID# 241030

    Scottsdale, Arizona

  • Burke Pharmaceutical Research /ID# 240811

    Hot Springs, Arkansas

  • UCSF Fresno /ID# 240903

    Fresno, California

  • Medderm Associates /ID# 240729

    San Diego, California

  • Clinical Trials Research Institute /ID# 240642

    Thousand Oaks, California

  • CCD Research, PLLC /ID# 240728

    Cromwell, Connecticut

  • Skin Care Research Boca Raton /ID# 240758

    Boca Raton, Florida

  • Apex Clinical Trials /ID# 248558

    Brandon, Florida

  • GSI Clinical Research, LLC /ID# 240901

    Margate, Florida

  • Florida International Rsrch cr /ID# 240902

    Miami, Florida

  • Park Avenue Dermatology, PA /ID# 240807

    Orange Park, Florida

  • Duplicate_TruDerm Dermatology of Wellington /ID# 240780

    Wellington, Florida

  • Dawes Fretzin, LLC /ID# 240701

    Indianapolis, Indiana

  • Beth Israel Deaconess Medical Center /ID# 240683

    Boston, Massachusetts

  • Revival Research Institute, LLC /ID# 241020

    Troy, Michigan

  • MediSearch Clinical Trials /ID# 240810

    Saint Joseph, Missouri

  • Washington University-School of Medicine /ID# 240797

    St Louis, Missouri

  • Advanced Dermatology of the Midlands /ID# 249750

    Omaha, Nebraska

  • Duplicate_Skin Specialists, PC /ID# 240804

    Omaha, Nebraska

  • Schweiger Dermatology, P.C. /ID# 240900

    New York, New York

  • Mount Sinai Doctors Dermatology /ID# 241588

    New York, New York

  • Montefiore Medical Center /ID# 240853

    The Bronx, New York

  • Essential Medical Research, LLC /ID# 241807

    Tulsa, Oklahoma

  • Center for Clinical Studies - Houston (Binz) /ID# 240692

    Houston, Texas

  • Duplicate_Paratus Clinical Research Woden /ID# 240605

    Phillip, Australian Capital Territory, Australia

  • Momentum Clinical Research /ID# 240911

    Darlinghurst, New South Wales, Australia

  • Premier Specialist /ID# 241288

    Kogarah, New South Wales, Australia

  • Veracity Clinical Research /ID# 241096

    Woolloongabba, Queensland, Australia

  • Beacon Dermatology Inc /ID# 240741

    Calgary, Alberta, Canada

  • Wiseman Dermatology Research /ID# 240738

    Winnipeg, Manitoba, Canada

  • Lima's Excellence in Allergy and Dermatology Research Inc /ID# 240814

    Hamilton, Ontario, Canada

  • Ryan Clinical Research Inc /ID# 247986

    Newmarket, Ontario, Canada

  • Dre Angelique Gagne-Henley M.D. inc. /ID# 240739

    Saint-Jérôme, Quebec, Canada

  • Havelklinik /ID# 240874

    Berlin, Germany

  • Klinikum Ruhr Univ Bochum /ID# 240870

    Bochum, Germany

  • Staedtisches Klinikum Dessau /ID# 240871

    Dessau, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 240873

    Hamburg, Germany

  • Duplicate_Universitaetsklinikum Erlangen /ID# 240872

    Erlangen, Bavaria, Germany

  • General Hospital of Thessaloniki Hippokrateio /ID# 240697

    Thessaloniki, Greece

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.